Yasuharu Nakahara - Concepedia

Author

Yasuharu Nakahara

Also Known As

Nakahara, Y., Ryogo Kagami, Y Nakahara, Y. Nakahara, YASUHARU NAKAHARA, Yasuharu NAKAHARA, Yasuharu Nakahara, Yuki Nakahara

114

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Himeji Medical Center National Hospital Organization Okayama University Hospital Hospital Universitario 12 De Octubre AstraZeneca (United States)

About

Yasuharu Nakahara is an author at Himeji Medical Center specializing in medicine, pathology, and pulmonary medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	3.5K
2	Immunology	3	3	39
3	Allergy	2	2	26
4	Health Sciences	1	1	14
5	Biology	1	1	14

Yasuharu Nakahara

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, The Lancet Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment	2019	2.1K
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, The Lancet Oncology Platinum–etoposide Versus Platinum–etoposideMedicinePathologyImmune Checkpoint InhibitorFirst-line Treatment	2020	662
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, The Lancet Oncology MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology	2019	594
A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402) Toshihide Yokoyama, Hiroshige Yoshioka, Daichi Fujimoto, Lung Cancer MedicinePathologyPhase Ii StudyBronchial NeoplasmFirst-line Treatment	2019	27
Factors associated with the relapse of cryptogenic and secondary organizing pneumonia Yasutaka Onishi, Tetsuji Kawamura, Yasuharu Nakahara, Respiratory Investigation Secondary Organizing PneumoniaPathogenesisPathologyRespiratory InfectionInfectious Respiratory Disease	2016	23
Prognostic significance of the lymphocyte‐to‐neutrophil ratio in percutaneous fine‐needle aspiration biopsy specimens of advanced nonsmall cell lung carcinoma Yasuharu Nakahara, Yoshiro Mochiduki, Yoshihiro Miyamoto, Cancer	2005	22
First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis Katsuyuki Hotta, Makoto Nishio, Haruhiro Saito, International Journal of Clinical Oncology	2021	20
Mental state as a possible independent prognostic variable for survival in patients with advanced lung carcinoma Yasuharu Nakahara Cancer	2002	19
<scp>IgG</scp>4‐related disease in asbestos‐related pleural disease Yasutaka Onishi, Yasuharu Nakahara, Katsuya Hirano, Respirology Case Reports	2015	18
[Case of idiopathic pulmonary upper lobe fibrosis]. Akie Morimoto, Yoshirou Mochizuki, Yasuharu Nakahara, PubMed Upper LobesInterventional PulmonologyPulmonary PathologyUpper LobeAdvanced Lung Disease	2010	18

Page 1